ClinicalTrials.gg
CompletedNCT07843056REORDERUpdated Sep 25, 2026

A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.

A Phase 2 interventional study of WAS123 and Aripiprazole (Fixed dose) in Schizophenia Disorder, sponsored by EMS. Completed at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by EMS · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 4 months after the study started (first participant enrolled May 2022, registered Sep 2026).
Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Schizophrenia with a site in Brazil — 3 open to participants now, 3 under way, 2 of them phase 3. Schizophrenia · Brazil.

Enrollment
34th of 57
121 · median 163
Started
2022
with 2 others
Phase 2
9 of 61
1 open now
Registered
61st of 61
by date

Among the 61 studies in Schizophrenia with a site in Brazil, this one is the 34th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 in phase 2, and was the 61st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 61 studies in Schizophrenia with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Schizophrenia with a site in Brazil, or all of them as a file.
02

Study summary

A phase II, proof-of-concept, national, multicenter, randomized, double-blind clinical trial to compare the efficacy and safety of WAS123 in the maintenance treatment of patients with schizophrenia, with a parallel design between 2 groups and controlled by an active comparator (Aripiprazole).

A total of 121 participants were randomized and assigned to either 1 of 2 treatment groups in a 1:1 ratio.

Read the detailed description

Aripiprazole is an atypical antipsychotic for the maintenance treatment of acute and chronic schizophrenia and bipolar 1 disorder in adults. This was a phase II, proof-of-concept, national, multicenter, randomized, double-blind clinical trial to compare the efficacy and safety of WAS123 in the maintenance treatment of patients with schizophrenia, with a parallel design between 2 groups and controlled by an active comparator (Aripiprazole).

Primary Objective: To evaluate the non-inferiority in efficacy of the WAS123 compared to the dosage of Aripiprazole in the overall symptomatic control of participants with schizophrenia.

Methodology: A total of 121 participants were randomized, and assigned to 1 of the 2 treatment arms of the trial in a 1:1 ratio.

This was a double-blind trial, no participant or person involved in its conduct, including those people responsible for data management, were aware of the allocation of treatments to participants.

Diagnosis and Main Criteria for Inclusion and Exclusion: The trial target population was made up of adults of both sexes aged 18 or over and 65 or under diagnosed with schizophrenia according to the DSM-5 diagnostic criteria. Participants were ineligible if they had another psychiatric disorder with psychotic symptoms other than schizophrenia or with schizophrenia refractory or resistant to antipsychotic treatment.

Duration of Treatment: The treatment period for the trial consisted of a mandatory 8-week (56-day) run-in for symptom stabilization, followed by randomization and 12 weeks (90 days) of treatment with the trial medications , totaling 20 weeks.

Statistical Methods:

The primary endpoint was analyzed using a generalized linear model including treatment effect and baseline as covariate and parameters were estimated by maximum likelihood. The treatment effect was expressed as the difference between the trial medication and the comparator, and a 95% confidence interval (CI) for this difference was calculated. Non-inferiority was concluded if the upper limit of the 95% CI was less than the pre-specified non-inferiority margin. As a sensitivity analysis, the same model was applied to data from the mITT set.

AEs, diseases, and comorbidities were coded using MedDRA. Safety analyses were descriptive and summarized vital signs, clinical, laboratory, and physical examination findings, as well as all AEs. AE frequencies were presented by treatment group according to causality, intensity, frequency, and severity.

03

Conditions studied

  • Schizophenia Disorder

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 18 to 65 years with the ability to confirm voluntary participation and who agreed to all trial purposes by signing and dating the ICF in duplicate.
  2. Diagnosis of schizophrenia according to diagnostic criteria and who:

    • At Screening:

      • Were stable on aripiprazole, considering a minimum period of 4 weeks without dose adjustment, or
      • Had an inadequate response to another antipsychotic; or
      • Had tolerance issues (e.g., extrapyramidal symptoms, metabolic problems) with the current antipsychotic; or
      • Were treatment-naive
    • At randomization:

      • Were stable on aripiprazole, considering a minimum period of 4 weeks without dose adjustment.
      • Participants who met all of the following criteria were considered stable:
      • Not hospitalized;
      • Total Positive and Negative Syndrome Scale (PANSS) score ≤80;
      • Score ≤4 on individual PANSS items (P1, P2, P3, and P6);
      • CGI-S score ≤4 (moderately ill);
      • CGI-SS score ≤2 (mildly suicidal)

Exclusion criteria

Exclusion Criteria:

  1. Any clinical or laboratory findings that were interpreted by the principal investigator as a risk to the participant's participation in the clinical trial or the presence of uncontrolled chronic disease(s);
  2. Participants with schizophrenia or resistant to antipsychotic treatment (therapeutic failure with 2 different antipsychotics, after treatment for at least 4 weeks at the maximum tolerated dose);
  3. Participants who had not responded adequately to previous aripiprazole trials;
  4. Participants who had used depot antipsychotics or undergone electroconvulsive therapy in the last 3 months;
  5. History of organic mental disorders, moderate to severe intellectual disability, or another psychiatric disorder with psychotic symptoms other than schizophrenia;
  6. History of epilepsy, neuroleptic malignant syndrome, tardive dyskinesia, or other medical condition that would expose the participant to undue risk or interfere with trial assessments;
  7. Diagnosis of substance dependence, including alcohol and benzodiazepines, but excluding nicotine and caffeine;
  8. Participants with previous cardiac events, such as tachycardia or bradyarrhythmias, or any significant prolongation of the on the (ECG);
  9. Participants who were pregnant, breastfeeding, or planning to become pregnant, or female participants of who were not using a reliable method of ;
  10. Participants with known allergy or to the components of the medications used during the clinical trial;
  11. Research participant who participated in clinical trial protocols in the last 12 months (CNS Resolution 251, of August 7, 1997, item III, subitem J), unless the investigator considered that there could be direct benefit to them.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    WAS123

    oral dose

    Drug: WAS123

  • Active comparator
    Aripiprazole

    oral daily dose

    Drug: Aripiprazole (Fixed dose)

Interventions

06

What researchers measure

Primary outcomes

  1. Score PANSS

    To evaluate the non-inferiority in efficacy of the WAS123 compared to the dosage of Aripiprazole in the overall symptomatic control of participants with schizophrenia.

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

1 site
  • Clinica Viver
    São Paulo, São Paulo, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data that support the reported results may be made available upon reasonable request and subject to Sponsor review and approval, after publication of the primary study results.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jan 2026, 44 months.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 44 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 25, 2026
StartActual
May 10, 2022
Primary completionActual
Jan 20, 2026
CompletionActual
Mar 23, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843056
Lead sponsor
EMS
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Sep 25, 2026
Start date
May 10, 2022
Primary completion
Jan 20, 2026
Completion
Mar 23, 2026
Last update
Sep 25, 2026

Study contacts

Cassiano Berto
study director · Grupo EMS S.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion